Feb 161 min read

Funicular Funds Supports for Strategic Review at Synlogic, Inc (SYBX)

Key Summary: Funicular Funds applauds the Board's prompt response. They aim to contribute to the strategic review process.

Market Cap: $17 million| Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States.

On February 16, 2024, Funicular Funds (36%) extends condolences for a clinical setback and applauds the Board's prompt response. They aim to contribute to the strategic review process. Source

Recent Posts

See All

Camac Fund, ATG Capital Management and McIntyre Capital (together 7.6%) entered into a settlement agreement with Forte Biosciences (FBRX)

Key Summary: Various investment firms, including BML Investment Partners, Camac Fund, ATG Fund, McIntyre Capital, and Funicular Funds,...

Starboard reaches agreement with Alight Inc (ALIT)

Key Summary: On Feb 16, 2024, Starboard nominated Board candidates for Alight Inc. On May 6, 2024, following a cooperation agreement with...

Bitfarms (BITF) and Riot Announce Settlement

Key Summary: On June 12, 2024, Riot Platforms criticized Bitfarms' 15% Poison Pill as poor governance and called for Chairman Nicolas...

Funicular Funds Supports for Strategic Review at Synlogic, Inc (SYBX)

Recent Posts

Comments

snowball research